Treatment of spinocerebellar ataxia with buspirone.
Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.
Assadi
Mitra
M
Department of Medicine, Division of Neurology, Cooper University Hospital/Robert Wood Johnson Medical School, Camden, New Jersey, USA. Assadi-Mitra@cooperhealth.edu
Campellone
Joseph V
JV
Janson
Christopher G
CG
Veloski
J Jon
JJ
Schwartzman
Robert J
RJ
Leone
Paola
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D002065:Buspirone / Q000008:administration & dosage* / Q000009:adverse effects; D018592:Cross-Over Studies; D004252:DNA Mutational Analysis; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005820:Genetic Testing; D006801:Humans; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D015990:Placebo Effect; D012701:Serotonin / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D012894:Sleep Stages / Q000187:drug effects; D020754:Spinocerebellar Ataxias / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D016896:Treatment Outcome
D017366:Serotonin Receptor Agonists; D012701:Serotonin; D002065:Buspirone